FDA approval of Lipfendra is bringing new attention to bad cholesterol, especially in Southeast Louisiana, where high levels are more common than average. The pill gives doctors another option to discuss with patients who are trying to lower LDL and protect long-term health.
In New Orleans, WWL Louisiana found that many people knew only pieces of their cholesterol story. Some had numbers, some had guesses, and some simply knew they wanted to stay healthy longer. That everyday confusion is exactly why this approval matters.
Southeast Louisiana has a higher-than-average percentage of people living with high cholesterol, according to WWL Louisiana. That makes the Lipfendra approval feel local, not abstract, because bad cholesterol is already part of routine health concerns across the New Orleans area.
WWL Louisiana stopped people in the French Quarter and asked if they knew their cholesterol numbers, the difference between good and bad cholesterol, and why it matters. Some knew pieces, some only knew total numbers, and others admitted they were guessing.
Shelly Hudson said, “They said my good is better than the bad,” then admitted she did not really know what it meant. Chana Franks put the goal more simply: people want to stay healthy as long as they can, especially while aging.
Dr. Frank Wilklow, senior cardiologist with LCMC Health at Touro, told WWL Louisiana that lower LDL means a lower chance of cardiovascular events, including strokes and heart attacks. His point is simple: bad cholesterol is dangerous because it builds quietly.
He explained that bad cholesterol can lay down plaque that clogs arteries, cutting into the blood flow organs need to function. HDL, often called good cholesterol, works differently. It helps mop up the bad cholesterol before that buildup causes deeper trouble.
Wilklow tied high LDL to strokes, dementia, heart attacks, and kidney disease, which is why numbers matter before symptoms appear. Cholesterol is not only a lab result. It is an early warning about what may be happening inside the arteries.
Lipfendra is drawing attention because it brings PCSK9 treatment into pill form, after years when this class was known mainly through injections. For patients who cannot get LDL low enough with statins, that gives doctors another option to discuss carefully.
Merck studies showed patients using Lipfendra with exercise had a nearly 60% decrease in high cholesterol, according to WWL Louisiana. That kind of reduction is why doctors see the new pill as a serious addition, not a small adjustment today.
Wilklow was even more direct, saying this medication class could mean fewer stents and fewer bypass surgeries in 10 years. The practical catch is access. Since Lipfendra was just FDA approved, insurance formularies may not include it right away.
Debate around Lipfendra is really about access, not just science. Until now, this PCSK9 treatment was only available as an injectable, so a pill could help patients who need stronger LDL control but hesitate around shots, cost, or daily routines.
Next chapters should focus on insurance formularies, manufacturer coupons, government discount options, and doctor guidance in Louisiana clinics. Lipfendra may lower LDL nearly by 60% in Merck studies, but real value comes when patients know their numbers and can actually get treatment.